According to a recent LinkedIn post from PictorLabs, the company is highlighting a scientific session at the DPAI 2026 meeting focused on virtual staining technologies. The session, led by the firm’s VP of Product, Megan Rothney, PhD, is scheduled for May 7 at The Ohio State University and is described as for research use only, not cleared or approved by the FDA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post outlines discussion topics including virtual H&E from unstained tissue, virtual special stains and IHC derived from existing H&E slides, and validation approaches against traditional staining methods. It also emphasizes the potential impact on workflow efficiency, particularly the ability to review tissue morphology before molecular workflows, which could influence tissue utilization in research settings.
For investors, the content suggests PictorLabs is positioning its virtual staining technology as a tool to address tissue constraints and optimize sample usage in digital and computational pathology. While regulatory clearance is not indicated, visibility at a specialized pathology meeting may support technology adoption in research environments and could lay groundwork for future clinical or commercial opportunities if validation and regulatory pathways advance.